Study on the Efficacy of Shugan Jieyu Capsules Combined with Trazodone in Patients with PostStroke Depression and Insomnia

Abstract

Objective: To analyze the effectiveness of applying ShuGan JieYu Capsules (SGJYC) combined with trazodone in patients with post-stroke depression (PSD) with insomnia. Methods: 60 cases of PSD with insomnia patients admitted to the hospital from May 2022 to May 2023 were selected and randomly divided into a reference group (trazodone) and a research group (SGJYC combined with trazodone) of 30 cases each. Statistics were analyzed using the Hamilton Depression Rating Scale (HAM-D), Pittsburgh Sleep Quality Index (PSQI), and Activities of Daily Living (ADL) scale before treatment and 4, 8, and 12 weeks after treatment. Results: Before treatment, The results of HAM-D, PSQI, and ADL scale studies in the two groups before treatment were not statistically significant (P > 0.05); 4, 8, and 12 weeks after treatment, the results of HAM-D and PSQI studies in the research group were lower than that of the reference group, and the results of ADL scale studies were higher than that of the reference group. There was a significant difference between the groups (P < 0.05). The total adverse reaction rate of the research group was lower than that of the reference group, and there was a significant difference between the groups (P < 0.05). Conclusion: The combination of SGJYC and trazodone reduced depression in post-stroke patients, corrected insomnia, improved sleep quality, was safe, and had a low rate of adverse reactions.